Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2009 1
2010 1
2011 2
2013 2
2014 5
2015 6
2016 1
2017 4
2018 3
2019 4
2020 10
2021 9
2022 9
2023 15
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab for cancer-associated refractory pruritus.
Talmon A, Elias S, Rubin L, Ribak Y, Ben Dori E, Shamriz O, Lotem M, Adini I, Tal Y. Talmon A, et al. Among authors: tal y. J Allergy Clin Immunol Glob. 2023 Jun 23;2(3):100128. doi: 10.1016/j.jacig.2023.100128. eCollection 2023 Aug. J Allergy Clin Immunol Glob. 2023. PMID: 37779518 Free PMC article.
Severe eosinophilia in hospitalized patients.
Tal Y, Hershcovich I, Talmon A, Ribak Y, Shamriz O, Toker O, Hershko AY. Tal Y, et al. J Intern Med. 2022 Mar;291(3):377-379. doi: 10.1111/joim.13407. Epub 2021 Nov 11. J Intern Med. 2022. PMID: 34700358 Free article. No abstract available.
Successful ligelizumab treatment of severe refractory solar urticaria.
Hershkovitz Y, Khanimov I, Rubin L, Dranitzki Z, Talmon A, Ribak Y, Shamriz O, Levi A, Tal Y. Hershkovitz Y, et al. Among authors: tal y. J Allergy Clin Immunol Pract. 2023 Aug;11(8):2576-2577. doi: 10.1016/j.jaip.2023.01.052. Epub 2023 Feb 15. J Allergy Clin Immunol Pract. 2023. PMID: 36796509 No abstract available.
Isolated solar angioedema: A systematic review of the literature.
Aronovich A, Snast I, Lapidoth M, Leshem YA, Enk CD, Tal Y, Mimouni D, Hodak E, Levi A. Aronovich A, et al. Among authors: tal y. Photodermatol Photoimmunol Photomed. 2021 Sep;37(5):431-438. doi: 10.1111/phpp.12677. Epub 2021 Mar 27. Photodermatol Photoimmunol Photomed. 2021. PMID: 33738834 Review.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109
67 results